InterMune Inc., a Brisbane, California, biopharmaceutical company, has agreed to pay the government $36.9 million to resolve criminal charges and civil liabilities in connection with allegations of illegally promoting Actimmune for treatment of idiopathic pulmonary fibrosis (IPF) or lung scarring despite not receiving approval for such treatment by the U.S. Food and Drug Administration. This settlement resolves allegations that InterMune caused the submission of false claims for Actimmune that were not eligible for reimbursement because they were for unnecessary or off label uses. The FDA had approved Actimmune for treating immune system disorders.

For more information please click here.